Fractyl reports positive six-month Revita weight-maintenance trial results

Fractyl Health said its Revita DMR System helped patients retain approximately 80% of GLP-1-induced weight loss six months after treatment ended, versus 67% for sham participants. Average weight regain was 5.1% with Revita and 8.2% with sham, producing p=0.0023 in the 308-participant REMAIN-1 study. The company intends to seek FDA De Novo review during late Q4 2026, with 12-month results expected in Q1 2027 and a potential U.S. launch in early 2028.

The results advance Revita toward regulatory review and support Fractyl's effort to develop a procedural option for post-GLP-1 weight maintenance. Commercialization still depends on the remaining 12-month assessment and FDA authorization.

  • 1REMAIN-1 was a randomized, double-blind, sham-controlled study involving 308 participants with obesity.
  • 2A post hoc analysis found that 32% of Revita recipients were weight stable or had lost additional weight at six months, compared with 18% of sham recipients.
  • 3The Revita procedure received CPT code 1122T, which takes effect January 1, 2027.
  • 4Fractyl reported no serious adverse events attributed to the device or procedure as of the September 24, 2026 data cutoff.

Sources